A carregar...
Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study
BACKGROUND: This phase 3 trial is the first to evaluate the efficacy and safety of treatment with the systemic TNF‐α inhibitor, adalimumab, for Chinese patients with moderate‐to‐severe plaque psoriasis. METHODS: In the 12‐week, double‐blind, placebo‐controlled Period A, patients were randomized 4 :...
Na minha lista:
Publicado no: | J Eur Acad Dermatol Venereol |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
John Wiley and Sons Inc.
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215651/ https://ncbi.nlm.nih.gov/pubmed/27504914 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.13746 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|